Syngene International Ltd Q1 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/1xo06favdgsn1wwnds0w4l3i.pdf

Key Takeaways


The Biologics Capacity Build-Out

Hunt: "Together, these actions show meaningful progress on our strategy to become a global leader in both research services (CRO) and manufacturing services (CDMO) and give us the capacity we need for the next stage of growth."

Manufacturing & Regulatory Milestones


Research Services Expansion


Margin & Cost Structure

Biswas: "We are pleased to report a solid start to the year. The financial performance is in line with the revenue growth guidance for the year on a constant currency basis. At 25%, EBITDA growth reflects better operating leverage as we gain scale in development and manufacturing services."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growthFinancial performance in line with constant-currency revenue growth guidance for the yearFY24
Stelis acquisition closeAcquisition of biologics manufacturing facility in Bangalore to completeEnd of Q3 FY24
Stelis facility operationalFacility to become operational following upgrades and re-validation2024
Hyderabad construction startProcure statutory clearances and commence construction on 17-acre land2024
Balance sheet strengthMaintain strong balance sheet and low debt profile despite investmentsOngoing

Key Metrics

MetricQ1 FY24
Revenue from operations₹808 cr, +25% YoY
Reported revenue₹832 cr, +26% YoY
Reported EBITDA₹235 cr, +25% YoY
Reported EBITDA margin28.3%, vs 28.5% in Q1 FY23
EBITDA from operations₹212 cr, +22.6% YoY
EBITDA from operations margin26.2%, down 59 bps YoY
PAT before exceptional item₹93 cr, +26% YoY
PAT margin11.2%, flat YoY
EBIT₹133 cr, +30.5% YoY
PBT₹123 cr, +32.5% YoY
Material costs27.6% of revenue from operations, vs 25.0% in Q1 FY23
Staff costs28.3% of revenue from operations, vs 30.6% in Q1 FY23
Foreign exchange loss₹15.5 cr, vs loss of ₹3.4 cr in Q1 FY23
Cash and cash equivalents₹260 cr as of June 30, 2023, vs ₹90 cr as of March 31, 2023
Total equity₹3,844 cr as of June 30, 2023, vs ₹3,618 cr as of March 31, 2023